Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and immunohistochemistry algorithms

摘要

BackgroundPatients with diffuse large B-cell lymphoma (DLBCL) exhibit widely divergent outcomes despite harboring histologically identical tumors. Currently, gene expression profiling (GEP) and immunohistochemistry algorithms (IHC) assign patients to one of two main subtypes: germinal center B-cell-like (GCB), or activated B-cell-like (ABC), the latter of which historically carries a less favorable prognosis. However, it remains controversial as to whether these prognostic groupings remain valid in the era of rituximab therapy.